AFFILIATIONS
1 Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States
2 University of Utah School of Medicine, Salt Lake City, Utah, United States
3 University of Utah School of Medicine, Salt Lake City, Utah, United States
4 Washington University School of Medicine in St. Louis, St. Louis, Missouri, United States
5 Texas Children’s Hospital and Baylor College of Medicine, Houston, Texas, United States
6 Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States
7 Yale School of Medicine, New Haven, Connecticut, United States
8 Department of Pediatrics, Nemours Children's Health Delaware and the Sidney Kimmel, Wilmington, Delaware, United States
9 Children’s National Hospital, The George Washington University School of Medicine and Health Sciences,, Washington DC, Maryland, United States
10 Children’s National Hospital, The George Washington University School of Medicine and Health Sciences,, Washington DC, Maryland, United States
11 University of Utah School of Medicine, Salt Lake City, Utah, United States
12 Children’s Hospital Los Angeles and Keck School of Medicine of the University of Southern California, Los Angeles, California, United States
13 Duke University School of Medicine, Durham, North Carolina, United States
14 Nationwide Children’s Hospital, Columbus, Ohio, United States
15 Medical College of Wisconsin, Milwuakee, Wisconsin, United States
16 Texas Children’s Hospital and Baylor College of Medicine, Houston, Texas, United States
17 Seattle Children's Hospital, University of Washington, Seattle, Washington, United States
18 Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
19 Washington University School of Medicine in St. Louis, St. Louis, Missouri, United States
20 Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States
21 University of California, San Francisco, California, United States
22 Children's Healthcare of Atlanta, Atlanta, Georgia, United States, Department of Pediatrics, Division of Pediatric Emergency Medicine, Emory University School of Medicine, Atlanta, Georgia, United States
23 Medical College of Wisconsin, Milwuakee, Wisconsin, United States
24 Texas Children’s Hospital and Baylor College of Medicine, Houston, Texas, United States
25 Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
26 UCSF Benioff Children’s Hospitals, Oakland, California, United States
27 Nationwide Children’s Hospital, Columbus, Ohio, United States
28 Children's Healthcare of Atlanta, Atlanta, Georgia, United States
29 Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States
30 Children's Healthcare of Atlanta, Atlanta, Georgia, United States, Department of Pediatrics, Children's Healthcare of Atlanta, Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, Atlanta, GA, Atlanta, Georgia, United States
31 Children's Healthcare of Atlanta, Atlanta, Georgia, United States, Department of Pediatrics, Division of Pediatric Emergency Medicine, Emory University School of Medicine, Atlanta, Georgia, United States
ABSTRACT
Background: Acute chest syndrome (ACS) and vaso-occlusive pain episodes (VOE) are closely interrelated in children with SCD, and ACS commonly develops as a complication of SCD-VOE hospitalization, often prolonging length of stay (LOS). Over the last 25 years, LOS for SCD-VOE has significantly diminished across the US from approximately 7 days to <72 hours. This reduction may limit the potential impact of additional interventions aimed at further shortening LOS. Multiple studies have confirmed that ACS is associated with an acute arginine (Arg) deficiency. It remains unknown if patients with ACS may uniquely benefit from Arg therapy or if ACS represents a subgroup of VOE where LOS remains long enough to measure a difference.
Objective: Evaluate the efficacy of intravenous (IV) Arg for patients with SCD- and ACS.
Methods: A planned, secondary analysis of patients diagnosed with ACS participating in a prospective, multicenter, phase-3 RCT of IV Arg in subjects age 3-21 years with SCD-VOE requiring IV opioids, conducted at 10 US sites utilizing the Pediatric Emergency Care Applied Research Network (PECARN). Within 12 hours of receiving their first dose of IV opioids, enrolled participants were randomized to receive either a one-time loading dose of IV Arg (200 mg/kg with a max of 20g) followed by a standard dose of 100 mg/kg (max 10g three times/day) or placebo (normal saline). The primary outcome was time-to-crisis-resolution (TCR), defined as the time in hours from study drug delivery to the last dose of IV opioid delivery. ACS was defined by a radiologist-interpreted CXR positive for a new infiltrate in the presence of fever/respiratory symptoms. Respiratory support, defined as any oxygen use was analyzed between groups. Univariable and multivariable analyses were performed to identify factors associated with a longer TCR. This protocol utilized FDA-IND#66943, registered with ClinicalTrials.gov (NCT04839354).
Results: The STArT trial was halted early for futility to reach the primary outcome of TCR after 271 patients received study drug (129-Arg, 142-placebo). TCR and LOS strongly correlate (r=0.86, p<0.001). The prevalence of ACS in this cohort was 20% (54/271), with 35% of whom were diagnosed in the ED, and 65% diagnosed during hospital admission. Median age of ACS patients was 13 [9, 16] years and 81% were on hydroxyurea. Patients with ACS were predominantly male (74%) and carried a more severe sickle genotype (SS or Sb0; 91%) vs patients without ACS. Clinical outcomes were worse in patients with ACS regardless of study arm, with longer median TCR (101 [60, 141] hours, n=54 vs 58 [28, 94] hours, n=217, p<0.001), LOS (137 [92, 189] vs 72 [46, 113] hours, p<0.001), and more than double total parenteral opioid use (2.3 [0.8, 3.9] vs 1.1 [0.4, 2.1] mg/kg, p=0.001) vs patients with VOE and no ACS. In both unadjusted and adjusted regression analyses, only ACS was significantly associated with a longer TCR when combining study arms (n=271). ACS patients had a mean 76-hour shorter TCR in the Arg arm vs placebo (108±98, n=29 vs 179±329, n=25; p=0.18; median difference=34 hours). TCR was achieved at 72-hours in 48% vs 20% of patients with ACS receiving Arg vs. placebo respectively (p=0.045). A greater number of patients receiving Arg were free of any respiratory support throughout their hospitalization vs placebo (28% vs 16% respectively), with the difference approaching significance by day 3 (p=0.08). Patients receiving Arg were >2 times less likely to experience oxygen desaturations <92% vs placebo, for both ACS patients and the entire cohort, a phenomenon that became statistically significant regardless of ACS status in those who experienced a desaturation<89% (p=0.04).
Conclusion: In this subgroup of patients with SCD-ACS Arg therapy showed a trend towards decreasing LOS and TCR, with a statistically significant difference in crisis resolution at 72 hours in patients with ACS. Notably patients treated with Arg were less likely experienced oxygen desaturations. To better understand the impact of Arg therapy on ACS, clinical endpoints that focus on objective measures like oxygen desaturation and need for respiratory support are biologically relevant and warrant further validation. ACS may represent a SCD subgroup who benefit from arginine therapy and sufficiently powered controlled trials are needed.